San Diego, California–(Newsfile Corp. – August 24, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today it has completed the training of psychotherapists for its upcoming Phase 2a clinical trial using synthetic psilocybin in combination with…
